Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 27;13(1):173.
doi: 10.1038/s41408-023-00948-x.

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Miao Wang #  1   2 , Han-Yu Cao #  1   2 , Kai-Wen Tan #  1   2 , Qiao-Cheng Qiu  1   2 , Yuan-Hong Huang  1   2 , Shuai-Shuai Ge  1   2 , Zi-Hao Wang  1   2 , Jia Chen  1   2 , Xiao-Wen Tang  1   2 , De-Pei Wu  1   2 , Sheng-Li Xue  3   4 , Zheng Li  5   6 , Hai-Ping Dai  7   8
Affiliations

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study

Miao Wang et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Study design, response outcomes, survival analysis, and mutational landscape of the unmatched VEN+HMA cohort.
a Flow chart of inclusion of patients for propensity score matching analysis. b Treatment response of matched patients to the first course of induction treatment with VEN + HMA or standard 7 + 3. c Relapse-free survival in the matched cohorts. d Overall survival in the matched cohorts. e Mutational landscape of the unmatched 21 patients treated with VEN + HMA. Oncoprint shows mutational characteristics at diagnosis. Patients are grouped by best response after 1–2 induction cycles and are labeled with colored bars on the right. The filled bars on the right show the percentage of patients achieving CRc in the presence of each gene mutation. The asterisk indicates genes with a P < 0.05 percentage of CRc.
See this image and copyright information in PMC

References

    1. Sanderson RN, Johnson PRE, Moorman AV, Roman E, Willett E, Taylor PR, et al. Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia. Leukemia. 2006;20:444–50. doi: 10.1038/sj.leu.2404055. - DOI - PubMed
    1. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–11. doi: 10.1200/JCO.2006.06.9500. - DOI - PubMed
    1. Wang B, Zhang J, Hua X, Li H, Wang Z, Yang B. Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia. Sci Rep. 2020;10:685. doi: 10.1038/s41598-020-57414-y. - DOI - PMC - PubMed
    1. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31:3360–8. doi: 10.1200/JCO.2012.47.4874. - DOI - PubMed
    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. - DOI - PubMed

Publication types

MeSH terms

Substances